Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

8 October 2014

Ultra-rapid formulations of the currently marketed rapid-acting insulin analogs have the clear potential to radically change the insulin market over the next five years, new research states.

According research and consulting firm GlobalData’s Valentina Gburcik, director of cardiovascular and metabolic disorders, the use of long-acting insulin analogs may decrease as rapid- and ultra-rapid-acting analogs gradually take over the type 1 diabetes market.

Dr Gburcik explains: “A substantial and ongoing rise in insulin pump usage over recent years, alongside the rapid development of a closed-loop system, or artificial pancreas, strengthens the need for insulins that act even faster than the currently marketed rapid-acting analogs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK